Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Oncotelic Therapeutics, Inc. | d124220dex312.htm |
| EX-32.1 - EX-32.1 - Oncotelic Therapeutics, Inc. | d124220dex321.htm |
| EX-31.1 - EX-31.1 - Oncotelic Therapeutics, Inc. | d124220dex311.htm |
| 10-K - 10-K - Oncotelic Therapeutics, Inc. | d124220d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| 1. | Registration Statements (Form S-3 Nos. 333-204333, 333-196589, 333-191531, 333-188114, 333-165826, 333-160976, 333-155372, 333-106307, 033-64968, 333-15241 and 333-12867) of OXiGENE, Inc., |
| 2. | Registration Statement (Form S-8 Nos. 333-126636, 333-177628, 333-181810 and 333-190409) pertaining to the OXiGENE, Inc. 2005 Stock Plan, as amended, |
| 3. | Registration Statement (Form S-8 No. 333-159585) pertaining to the OXiGENE, Inc. 2005 Stock Plan and the OXiGENE, Inc. 2009 Employee Stock Purchase Plan, and |
| 4. | Registration Statement (Form S-8 No. 333-204500) pertaining to the OXiGENE, Inc. 2015 Equity Incentive Plan; |
of our report dated March 25, 2016, with respect to the financial statements of OXiGENE, Inc., included in this Annual Report (Form 10-K) of OXiGENE, Inc. for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Redwood City, California
March 25, 2016